New drug reparixin aims to control myelofibrosis when standard treatment fails

NCT ID NCT05835466

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests the drug reparixin in 10 people with myelofibrosis, a type of bone marrow cancer. Participants have advanced disease and cannot take or have not responded to standard JAK inhibitor therapy. They take reparixin pills three times daily for 6 months, with the option to continue if the disease is stable. The goal is to see if reparixin can shrink the spleen, improve anemia, and reduce symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: reparixin
What this could lead to: If successful, reparixin could offer a new treatment option for myelofibrosis patients who cannot use or have failed standard JAK inhibitor therapy.
What could go wrong: This is a small early-phase trial with only 10 participants, so results may not apply broadly. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (PMF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS (PMF) POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF) POST POLYCYTHEMIA VERA RELATED MYELOFIBROSIS (PV-MF)

Contacts and locations

Locations

Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
NewYork-Presbyterian/Weill Cornell Medical Center
RECRUITING

New York, New York, 10065, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
Ruttenberg Treatment Center
RECRUITING

New York, New York, 10029, United States
The Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Wake Forest Baptist Health Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.